Rational clinical immunotherapy for multiple sclerosis

F. Samuel, M. D. Hunter, G. Brian, Brian G Weinshenker, L. Jonathan, M. D. Carter, H. John, M. D. Noseworthy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In this article, we assess the roles and the efficacy of immunopharmacologic agents in the treatment of multiple sclerosis (MS) and other demyelinating disease syndromes. The initial clinical manifestations of demyelinating disease, immunotherapeutic goals, efficacy of individual agents, and specific immunopharmacologic recommendations are discussed. MS and other idiopathic demyelinating disease syndromes can be effectively managed with immunotherapy. Exacerbations are treatable, and the frequency and severity of exacerbations can be reduced. Although some agents have a minor effect on progression of disability, current approaches have not proved to have a major influence on treatment of progressive MS. Immunotherapy for inflammatory demyelinating disease necessitates a high degree of clinical certainty about the diagnosis. Because all available therapeutic agents have limitations and significant toxic effects, careful consideration is necessary before use. Treatment should be individualized on the basis of the clinical course of the disease and the degree of patient disability.

Original languageEnglish (US)
Pages (from-to)765-780
Number of pages16
JournalMayo Clinic Proceedings
Volume72
Issue number8
StatePublished - 1997

Fingerprint

Demyelinating Diseases
Immunotherapy
Multiple Sclerosis
Poisons
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Samuel, F., Hunter, M. D., Brian, G., Weinshenker, B. G., Jonathan, L., Carter, M. D., ... Noseworthy, M. D. (1997). Rational clinical immunotherapy for multiple sclerosis. Mayo Clinic Proceedings, 72(8), 765-780.

Rational clinical immunotherapy for multiple sclerosis. / Samuel, F.; Hunter, M. D.; Brian, G.; Weinshenker, Brian G; Jonathan, L.; Carter, M. D.; John, H.; Noseworthy, M. D.

In: Mayo Clinic Proceedings, Vol. 72, No. 8, 1997, p. 765-780.

Research output: Contribution to journalArticle

Samuel, F, Hunter, MD, Brian, G, Weinshenker, BG, Jonathan, L, Carter, MD, John, H & Noseworthy, MD 1997, 'Rational clinical immunotherapy for multiple sclerosis', Mayo Clinic Proceedings, vol. 72, no. 8, pp. 765-780.
Samuel F, Hunter MD, Brian G, Weinshenker BG, Jonathan L, Carter MD et al. Rational clinical immunotherapy for multiple sclerosis. Mayo Clinic Proceedings. 1997;72(8):765-780.
Samuel, F. ; Hunter, M. D. ; Brian, G. ; Weinshenker, Brian G ; Jonathan, L. ; Carter, M. D. ; John, H. ; Noseworthy, M. D. / Rational clinical immunotherapy for multiple sclerosis. In: Mayo Clinic Proceedings. 1997 ; Vol. 72, No. 8. pp. 765-780.
@article{13218fcec3c545ff8b7047d4973c1cb7,
title = "Rational clinical immunotherapy for multiple sclerosis",
abstract = "In this article, we assess the roles and the efficacy of immunopharmacologic agents in the treatment of multiple sclerosis (MS) and other demyelinating disease syndromes. The initial clinical manifestations of demyelinating disease, immunotherapeutic goals, efficacy of individual agents, and specific immunopharmacologic recommendations are discussed. MS and other idiopathic demyelinating disease syndromes can be effectively managed with immunotherapy. Exacerbations are treatable, and the frequency and severity of exacerbations can be reduced. Although some agents have a minor effect on progression of disability, current approaches have not proved to have a major influence on treatment of progressive MS. Immunotherapy for inflammatory demyelinating disease necessitates a high degree of clinical certainty about the diagnosis. Because all available therapeutic agents have limitations and significant toxic effects, careful consideration is necessary before use. Treatment should be individualized on the basis of the clinical course of the disease and the degree of patient disability.",
author = "F. Samuel and Hunter, {M. D.} and G. Brian and Weinshenker, {Brian G} and L. Jonathan and Carter, {M. D.} and H. John and Noseworthy, {M. D.}",
year = "1997",
language = "English (US)",
volume = "72",
pages = "765--780",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Rational clinical immunotherapy for multiple sclerosis

AU - Samuel, F.

AU - Hunter, M. D.

AU - Brian, G.

AU - Weinshenker, Brian G

AU - Jonathan, L.

AU - Carter, M. D.

AU - John, H.

AU - Noseworthy, M. D.

PY - 1997

Y1 - 1997

N2 - In this article, we assess the roles and the efficacy of immunopharmacologic agents in the treatment of multiple sclerosis (MS) and other demyelinating disease syndromes. The initial clinical manifestations of demyelinating disease, immunotherapeutic goals, efficacy of individual agents, and specific immunopharmacologic recommendations are discussed. MS and other idiopathic demyelinating disease syndromes can be effectively managed with immunotherapy. Exacerbations are treatable, and the frequency and severity of exacerbations can be reduced. Although some agents have a minor effect on progression of disability, current approaches have not proved to have a major influence on treatment of progressive MS. Immunotherapy for inflammatory demyelinating disease necessitates a high degree of clinical certainty about the diagnosis. Because all available therapeutic agents have limitations and significant toxic effects, careful consideration is necessary before use. Treatment should be individualized on the basis of the clinical course of the disease and the degree of patient disability.

AB - In this article, we assess the roles and the efficacy of immunopharmacologic agents in the treatment of multiple sclerosis (MS) and other demyelinating disease syndromes. The initial clinical manifestations of demyelinating disease, immunotherapeutic goals, efficacy of individual agents, and specific immunopharmacologic recommendations are discussed. MS and other idiopathic demyelinating disease syndromes can be effectively managed with immunotherapy. Exacerbations are treatable, and the frequency and severity of exacerbations can be reduced. Although some agents have a minor effect on progression of disability, current approaches have not proved to have a major influence on treatment of progressive MS. Immunotherapy for inflammatory demyelinating disease necessitates a high degree of clinical certainty about the diagnosis. Because all available therapeutic agents have limitations and significant toxic effects, careful consideration is necessary before use. Treatment should be individualized on the basis of the clinical course of the disease and the degree of patient disability.

UR - http://www.scopus.com/inward/record.url?scp=0031202937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031202937&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 765

EP - 780

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -